Clinical Trial

Genotype-Phenotype Correlations in Patients With Alport Syndrome

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 1, 2021 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Alport syndrome (AS) is caused by pathogenic variants in the type IV collagen genes COL4A3, COL4A4, and COL4A5. This study aims to enroll families and patients with a history of renal hematuria in 27 hospitals and detect these three genes for AS screening. This study also aims to analysis the effect of COL4A3/COL4A4/COL4A5 genotype on the development of kidney disease.
Trial Details
NCT Number NCT04947813
Lead Sponsor Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Conditions Alport Syndrome
Enrollment 8,165 participants
Start Date 2021-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2021-07-01